Skip to main
AXGN

AxoGen (AXGN) Stock Forecast & Price Target

AxoGen (AXGN) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axogen is one of the leaders in the market for peripheral nerve repair solutions, offering a range of innovative and clinically successful products. The recent FDA approval of its Avance nerve allograft adds to the company's impressive portfolio and increases its potential as a market leader. With a strong cash position and increasing sales in all three of its target markets, Axogen's revenue is expected to grow by at least 20% in 2026, providing a strong foundation for future growth and profitability.

Bears say

Axogen is highly dependent on reimbursement policies to drive demand for its nerve repair products, and any changes in government regulations or coverage could negatively impact sales. Additionally, the company has a concentrated product portfolio, making it vulnerable to competition from larger, well-capitalized medical device companies. While Axogen has no debt obligations and a clean capital structure, future dilution could occur should the company need to raise additional capital for infrastructure investment or M&A activities. Overall, the company faces significant risks that could hinder its growth and profitability in the long term.

AxoGen (AXGN) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AxoGen (AXGN) Forecast

Analysts have given AxoGen (AXGN) a Buy based on their latest research and market trends.

According to 8 analysts, AxoGen (AXGN) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AxoGen (AXGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.